Analysts: Viking’s PhII obesity drug could compete with Lilly’s Zepbound

Viking Therapeutics’ dual GLP-1/GIP receptor agonist for obesity showed off positive topline data from a Phase II study, with analysts describing the drug as a potential competitor to Eli Lilly’s Zepbound.

The biotech’s stock $VKTX jumped more than 90% on Tuesday following…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks